Block Dissections of Neck and Endolymphatic Sac: Treatment and Procedure — Cost, Top Hospitals & Success Rates | MyMedicPlus

This article covers two distinct but anatomically related surgical procedures performed by head and neck surgeons and neuro-otologists: neck dissection for the regional lymph node management of head and neck cancers, and endolymphatic sac (ELS) surgery for selected patients with Meniere's disease or endolymphatic sac tumours (ELST).

Neck dissection is a surgical operation to remove cervical lymph node groups — potentially harbouring metastatic cancer — together with varying amounts of adjacent non-lymphatic structures. It remains a cornerstone of head and neck surgical oncology, used both for N+ disease (clinically or radiologically involved nodes) and as elective treatment of the clinically N0 neck when occult metastasis risk exceeds approximately 15–20%. The fundamental classification — radical, modified radical, and selective — was standardised by Robbins et al. (1991, updated 2008) and adopted by the American Head and Neck Society (AHNS) and the Union for International Cancer Control (UICC).

Endolymphatic sac (ELS) surgery encompasses two different operations. Endolymphatic sac decompression (ELS decompression) is performed for refractory Meniere's disease, a condition characterised by episodic vertigo, fluctuating sensorineural hearing loss, tinnitus, and aural fullness caused by endolymphatic hydrops. ELS decompression aims to reduce endolymphatic pressure by surgically exposing and — in some techniques — shunting the endolymphatic sac. Separately, endolymphatic sac tumour (ELST) is a rare but locally aggressive low-grade adenocarcinoma arising from the ELS, strongly associated with von Hippel-Lindau (VHL) disease, requiring surgical resection with or without adjuvant radiotherapy.

Neck dissection — oncological indications:

• Oral cavity cancers (lip, tongue, floor of mouth, buccal mucosa): The ipsilateral neck (typically Levels I, IIA, III, IV) is treated electively when primary tumour depth of invasion exceeds 4 mm (T2+ tumours) due to the high risk (>20%) of occult nodal metastasis. N+ disease requires therapeutic ipsilateral and often contralateral dissection.
• Oropharyngeal cancer (tonsil, base of tongue, soft palate): Frequently associated with bilateral nodal involvement given midline location; p16/HPV-positive oropharyngeal cancers have excellent prognosis even with nodal metastases. Neck dissection follows primary chemoradiation for N2–N3 disease unless complete nodal response on post-treatment PET-CT (PETCT-guided selective dissection, UK POPART/PET-Neck trials).
• Laryngeal and hypopharyngeal cancers: Selective neck dissection of Levels II–IV is performed for T3–T4 glottic/supraglottic tumours at high risk of nodal spread. Total laryngectomy specimens include paratracheal node dissection (Level VI).
• Thyroid cancer: Central compartment neck dissection (Level VI) is indicated for medullary and for papillary thyroid cancers with clinical central nodal involvement. Lateral neck dissection (Levels II–V) is performed for biopsy-proven lateral nodal metastasis.
• Cutaneous head and neck malignancies: Melanoma of the head and neck with sentinel node-positive findings warrants selective nodal dissection based on drainage basin. Merkel cell carcinoma and high-risk squamous cell carcinoma of the skin are managed with parotid and selective neck dissection depending on primary site.

Endolymphatic sac surgery — indications:

• Refractory Meniere's disease: ELS decompression or ELS shunt is considered in patients with disabling episodic vertigo failing 6–12 months of conservative management (salt restriction, diuretics, betahistine) and intratympanic therapies. It is a hearing-sparing option compared with vestibular nerve section or labyrinthectomy.
• Endolymphatic sac tumour (ELST): These rare papillary adenocarcinomas arise from the ELS within the posterior petrous bone. Up to 15% of VHL patients develop ELSTs; bilateral ELST is pathognomonic of VHL disease. Symptoms include progressive sensorineural hearing loss, tinnitus, facial nerve palsy, and vestibular dysfunction. VHL genetic testing is recommended for all ELST patients.

For neck dissection:

• Imaging staging: All patients require pre-operative CT with contrast of the neck and chest (or PET-CT for selected cases) to assess nodal extent, extranodal extension (ENE), and vascular involvement (carotid artery encasement). MRI is superior for soft tissue assessment of the primary tumour.
• N0 neck management: The decision to treat the clinically N0 neck electively depends on primary site, T-stage, tumour depth of invasion, and the risk of occult metastasis. The threshold for elective neck dissection is generally ≥20% occult nodal metastasis risk. Sentinel node biopsy (SNB) is validated as an alternative to elective selective neck dissection in clinical T1–T2N0 oral cavity cancer (SENTINEL trial, Br J Cancer 2015): SNB has 86% sensitivity and equivalent disease-specific survival with significantly reduced morbidity.
• Functional assessment: Shoulder function should be documented pre-operatively (spinal accessory nerve, CN XI). Patients with pre-existing shoulder dysfunction, prior radiotherapy, or advanced disease affecting CN XI should receive pre-operative counselling and physiotherapy referral planning.
• Medical fitness: Neck dissection is a major procedure (typically 2–5 hours under general anaesthesia). Cardiorespiratory fitness, coagulation status (particularly in patients on anticoagulants), and nutritional status (pre-operative dietetic assessment for head and neck cancer patients) are assessed.

For ELS surgery:

• Audiometric baseline: Pure-tone audiometry and speech discrimination scores, electrocochleography (ECochG), and caloric vestibular testing (or video head impulse testing — vHIT) must be documented pre-operatively.
• Refractory to conservative therapy: NICE (2018) recommends ELS decompression only after exhausting medical management and lower-risk surgical options (intratympanic steroids, Meniett device). The American Academy of Otolaryngology-HNS guidelines similarly recommend conservative management as first-line.
• ELST staging: MRI with gadolinium enhancement and CT of the temporal bone are essential for ELST to define extent, bone erosion, and involvement of the endolymphatic duct. DSA or CTA may be required if major vascular involvement is suspected.

Neck dissection classification (Robbins/AHNS 2008):

• Radical neck dissection (RND): The original procedure (Crile 1906; Martin 1951) removes all five nodal levels (I–V) together with the sternocleidomastoid muscle (SCM), the internal jugular vein (IJV), and spinal accessory nerve (CN XI). It results in significant morbidity — shoulder dysfunction (CN XI sacrifice), neck contour deformity, and risk of facial oedema (bilateral IJV sacrifice). RND is now rarely performed; reserved for cases with direct tumour invasion of SCM, IJV, or CN XI.
• Modified radical neck dissection (MRND): Removes all five nodal levels (I–V) but preserves one or more of SCM, IJV, and CN XI. MRND Type III (Bocca dissection) preserves all three structures, producing equivalent oncological outcomes to RND for most head and neck cancers while substantially reducing morbidity. This is the most common "comprehensive" neck dissection performed.
• Selective neck dissection (SND): Removes specific node groups based on primary tumour drainage patterns while preserving non-lymphatic structures and uninvolved levels. The most common patterns are: Levels IIA–IV (oral cavity/oropharynx/larynx/hypopharynx); Level I–III (oral cavity); Levels II–IV (larynx); Level VI (thyroid/anterior larynx). SND has equivalent regional control to MRND in clinically N0 or N1 disease in most tumour sites.
• Extended neck dissection: Includes removal of additional nodal groups (retropharyngeal, parapharyngeal, superior mediastinal, paratracheal) or non-lymphatic structures (carotid artery, skin, strap muscles) beyond those removed in MRND. Extended dissection with carotid artery sacrifice carries significant risk of stroke and is considered only when carotid involvement precludes oncologically clear margins.
• Sentinel lymph node biopsy (SLNB): In T1–T2N0 oral cavity cancer, peritumoral injection of technetium-99m nanocolloid radioisotope (with or without patent blue dye) maps the sentinel node(s). Intraoperative gamma probe guidance identifies and excises the sentinel node(s) for frozen section and definitive pathological analysis. Positive SLN triggers completion selective neck dissection; negative SLN avoids full neck dissection. The SENTINEL multicentre RCT demonstrated non-inferior survival with SLNB versus selective neck dissection in T1–T2N0 oral cavity SCC.

Endolymphatic sac surgical procedures:

• ELS decompression (Thomsen/Portmann approach): Via a cortical mastoidectomy, the posterior fossa dura overlying the endolymphatic sac is exposed and the bony covering removed. Some surgeons additionally open the sac and insert a T-tube shunt (Gibson ELS-T shunt variant) to maintain patency. The procedure takes approximately 90–120 minutes under general anaesthesia.
• ELST resection: Requires a lateral skull base approach (combined translabyrinthine, retrosigmoid, or infralabyrinthine depending on tumour extent). Complete en-bloc resection with clear margins is the goal. Intraoperative facial nerve monitoring is mandatory. Postoperative gamma knife or fractionated stereotactic radiotherapy may be added for incompletely resected tumours or VHL-associated bilateral disease.

Neck dissection benefits:

• Regional disease control: Neck dissection provides definitive surgical control of cervical lymph node metastases, reducing the risk of regional recurrence which carries a poor prognosis (5-year survival after regional recurrence: approximately 15–25%). Combined with primary tumour resection, it achieves locoregional control rates of 80–90% for Stage I–III oral cavity cancers when combined with adjuvant radiotherapy where indicated.
• Accurate pathological staging: The pathological specimen provides crucial staging information: number of involved nodes, size of largest metastatic deposit, and — critically — presence or absence of extranodal extension (ENE). Pathological ENE (pENE) is the single most important adverse prognostic factor in head and neck cancer and mandates adjuvant concurrent chemoradiotherapy (cisplatin-based), improving local control and survival.
• Curative intent in N+ disease: For patients with resectable N1–N2 disease, neck dissection combined with adjuvant treatment offers a curative pathway. Modern functional-sparing selective neck dissection achieves equivalent oncological control to radical dissection in most situations with substantially reduced morbidity.
• Sentinel node biopsy accuracy: SNB in T1–T2N0 oral cavity cancer avoids unnecessary elective neck dissection in approximately 70–75% of patients (who are histologically node-negative), sparing them from the morbidity of full selective neck dissection whilst reliably identifying the 25–30% with occult nodal metastasis who require therapeutic dissection.

ELS decompression potential benefits:

• Vertigo control in Meniere's disease: Retrospective and non-randomised prospective series report vertigo improvement rates of 50–75% following ELS decompression, with lower rates of hearing preservation loss compared to more ablative procedures (vestibular neurectomy, labyrinthectomy). However, the absence of high-quality RCT evidence (confirmed by the NICE 2018 review) means it is difficult to attribute benefit beyond placebo effect.
• Hearing-sparing advantage: ELS decompression is a cochlear- and nerve-preserving procedure; the risk of procedure-related sensorineural hearing loss is lower than with intratympanic gentamicin or vestibular neurectomy, making it preferable in patients with useful hearing in the affected ear.
• ELST resection — oncological benefit: Complete surgical resection is the only potentially curative treatment for ELST. Gross total resection achieves long-term local control in the majority of patients. Adjuvant stereotactic radiosurgery (SRS) or fractionated radiotherapy is used for subtotal resection or VHL-associated bilateral disease to defer further hearing loss in the contralateral ear.

Neck dissection risks:

• Spinal accessory nerve (CN XI) injury: Even when CN XI is preserved in MRND, neuropraxia from traction or devascularisation produces temporary shoulder weakness and pain in 30–50% of patients. Permanent shoulder dysfunction (dropped shoulder, limited abduction, chronic pain) occurs in approximately 10–20% of MRND patients and is universal after RND. Physiotherapy commenced within 6–8 weeks of surgery significantly reduces long-term disability.
• Chyle leak: Injury to the thoracic duct or its tributaries during left-sided or bilateral neck dissection results in chylous fistula, presenting with milky drain fluid on refeeding. Management includes medium-chain triglyceride diet (enteral or oral) and pressure dressing; surgical re-exploration or lymphatic embolisation is required for high-output leaks (>500 mL/day unresponsive to conservative management).
• Nerve injuries: Marginal mandibular branch of facial nerve (CN VII) — lip asymmetry; lingual nerve — tongue sensation; hypoglossal nerve (CN XII) — tongue deviation; vagus nerve (CN X) — hoarseness, dysphagia; phrenic nerve — hemidiaphragm paralysis; sympathetic chain — Horner syndrome (ptosis, miosis, anhidrosis).
• Haematoma: Cervical haematoma complicates approximately 2–4% of neck dissections and requires urgent surgical evacuation to prevent airway compromise. Adequate haemostasis and drain placement at closure minimise risk.
• Wound infection and fistula: Particularly in patients with prior radiotherapy to the neck, wound breakdown and orocutaneous or pharyngocutaneous fistula can occur, requiring wound care, nasogastric nutrition, and sometimes further surgery.
• Extranodal extension (ENE) — pathological finding: Detection of pENE in the surgical specimen, while not a complication per se, significantly upstages the patient and mandates intensification of adjuvant treatment. Surgeons and oncologists must counsel patients about the possibility of this finding pre-operatively.

ELS surgery risks:

• Sensorineural hearing loss: Cochlear or cochlear nerve injury during mastoidectomy carries a low but real risk of procedure-related SNHL. In Meniere's disease, progressive hearing loss is inherent to the disease regardless of surgery.
• Facial nerve injury: The facial nerve courses through the mastoid and is at risk during posterior fossa dissection. Experienced lateral skull base surgeons with intraoperative facial nerve monitoring achieve permanent facial palsy rates below 1% for ELS decompression; risk is higher for ELST resection depending on tumour extent.
• CSF leak: Opening of the posterior fossa dura during ELS surgery can result in cerebrospinal fluid leak; most resolve with fat packing and wound closure under pressure but occasionally require lumbar drainage or re-exploration.
• Limited evidence for ELS decompression: The 2018 NICE evidence review of ELS decompression for Meniere's disease concluded that there is no RCT-level evidence supporting decompression over sham surgery. The only published sham-controlled trial (Thomsen et al., 1981, Denmark) showed no significant difference between ELS decompression and sham mastoidectomy in vertigo control at 1 year, raising the possibility that a placebo effect accounts for reported benefits.

After neck dissection:

• Immediate post-operative care: Patients are monitored for haematoma (particularly in the first 6 hours), airway patency, drain output (haemoserous vs chylous), and wound integrity. Surgical drains are removed when output is less than 30–50 mL per 24 hours. Hospital stay is typically 3–7 days depending on extent of dissection and whether simultaneous primary tumour surgery was performed.
• Pathology review and multidisciplinary team (MDT) discussion: The pathological report — number of involved nodes, largest node size, ENE status, resection margin status — is discussed at the head and neck MDT within 1–2 weeks of surgery. This determines the need for adjuvant treatment: adjuvant radiotherapy alone (positive margins without ENE) or concurrent chemoradiotherapy (pENE, two or more positive nodes, positive margins).
• Adjuvant radiotherapy planning: Where indicated, CT-based planning simulation is arranged within 4–6 weeks of surgery. Concurrent weekly cisplatin (40 mg/m²) is the standard radiosensitiser for high-risk features. IMRT (intensity-modulated radiotherapy) is standard to minimise xerostomia, dysphagia, and mandibular osteoradionecrosis.
• Shoulder rehabilitation: All patients undergoing neck dissection with CN XI dissection or manipulation should be referred to physiotherapy. Active-assisted exercises for shoulder abduction and external rotation commenced within 6–8 weeks significantly reduce long-term shoulder morbidity.
• Surveillance: Head and neck cancer surveillance: clinical examination at 1–2 monthly intervals for the first year, 3-monthly in year 2, 4–6 monthly in years 3–5. Post-treatment PET-CT at 12–16 weeks for N2–N3 disease (UK head and neck cancer guidance). Thyroid function annually if the neck received radiotherapy.

After ELS surgery:

• Vertigo and vestibular rehabilitation: Vestibular physiotherapy (Cawthorne-Cooksey exercises, gaze stabilisation exercises) is recommended for all patients post ELS surgery, particularly if any labyrinthine dysfunction has occurred. Audiometric re-assessment at 4–6 weeks post-operatively.
• VHL surveillance (ELST patients): All ELST patients without known VHL diagnosis should undergo germline VHL genetic testing and, if positive, enrolment in a multidisciplinary VHL surveillance programme including annual MRI of CNS/spine, renal, and pancreatic imaging per VHL Alliance and NICE guidelines.

The cost of neck dissection and ELS surgery varies substantially by procedure complexity, country, and healthcare system:

• Neck dissection cost range: In the United States, selective neck dissection as a standalone procedure costs approximately USD 8,000–18,000 (surgeon + anaesthesia + facility fees). When combined with primary tumour resection (e.g., glossectomy, laryngectomy), total surgical costs may reach USD 30,000–80,000. In India, neck dissection at accredited tertiary cancer hospitals costs approximately INR 80,000–3,00,000 (USD 1,000–3,600), offering significant savings for international patients.
• Adjuvant treatment costs: Adjuvant cisplatin-based concurrent chemoradiotherapy adds substantial costs — IMRT planning and delivery (30–35 fractions) costs USD 15,000–40,000 in the US; cisplatin 40 mg/m² weekly costs approximately USD 500–1,500 per cycle. These costs are substantially lower in Asia and Eastern Europe.
• Intraoperative neuromonitoring: Continuous intraoperative facial nerve monitoring during skull base or lateral neck surgery typically adds USD 500–1,500 to procedural costs but is considered standard of care and reduces permanent nerve injury rates.
• ELS decompression cost: As a day-case or short-stay (1–2 day) mastoidectomy procedure, ELS decompression typically costs USD 5,000–12,000 in the US private sector and is available in most countries with ENT surgical services. Given the limited evidence base, cost-effectiveness is uncertain.
• Medical tourism: Major academic cancer centres in India (Tata Memorial Hospital Mumbai, AIIMS Delhi, CMC Vellore), Thailand (Bumrungrad, Mahidol-affiliated), and South Korea (Severance, Samsung) offer head and neck oncological surgery to international patients at 20–40% of US costs, with comparable surgical expertise and pathological services. Accreditation (JCI/NABH) and institutional head and neck surgical volume are the most important quality indicators.

Alternatives to neck dissection:

• Primary (chemo)radiotherapy: For oropharyngeal, nasopharyngeal, and laryngeal cancers, definitive concurrent chemoradiotherapy (CRT) achieves equivalent locoregional control to surgery with organ preservation. Post-CRT PET-CT at 12–16 weeks with response-adapted neck dissection (only for incomplete nodal response) has replaced prophylactic post-CRT neck dissection in HPV-positive oropharyngeal cancer (UK PET-Neck trial: equivalent overall survival, significantly less morbidity).
• Sentinel node biopsy (SLNB): For T1–T2N0 oral cavity cancer, SNB avoids elective selective neck dissection in histologically node-negative patients whilst reliably capturing those with occult metastasis. SLNB is now guideline-endorsed at specialist centres performing adequate volume.
• Active surveillance of the N0 neck: In highly selected T1 oral cavity tumours (depth of invasion ≤4 mm), observation of the N0 neck with close clinical and ultrasound surveillance may be appropriate, with salvage neck dissection for regional recurrence. Salvage neck dissection after regional failure has a 60–70% success rate, making close surveillance a viable option in carefully selected cases.

Alternatives to ELS surgery for Meniere's disease:

• Conservative medical management: Low-sodium diet (less than 1,500 mg/day), diuretics (hydrochlorothiazide/triamterene or acetazolamide), and betahistine (16–48 mg three times daily) remain the cornerstone of initial Meniere's management and produce vertigo control in approximately 50–60% of patients.
• Intratympanic steroids: Intratympanic dexamethasone (4–12 mg/mL) injected through the tympanic membrane achieves vertigo control in 50–70% of patients in prospective studies, with negligible risk of hearing loss. It may require repeated courses.
• Intratympanic gentamicin: Selective chemical ablation of vestibular hair cells. Achieves vertigo control in 70–90% of patients but carries a 10–30% risk of permanent worsening of sensorineural hearing loss. Preferred for patients with poor residual hearing in the affected ear.
• Vestibular nerve section: Selective sectioning of the vestibular division of CN VIII via a middle fossa or retrosigmoid approach achieves vertigo control in over 90% of patients with preservation of cochlear nerve function. More invasive than ELS surgery but higher efficacy; requires lateral skull base neurosurgical expertise.
• Labyrinthectomy: Surgical destruction of the labyrinth achieves near-universal vertigo control but results in complete ipsilateral hearing loss. Reserved for patients with non-serviceable hearing in the affected ear with disabling refractory vertigo.